

Influenza B Victoria lineage egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2021 southern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

25 September 2020 (Last updated 20 November 2020)

Candidate vaccine viruses (antigenically like B/Washington/02/2019)

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Hong Kong/574/2019	Wild type virus			WHO CCs
	BX-87C	Classical	NYMC	NYMC, USA
B/Washington/02/2019	Wild type virus			WHO CCs NIBSC, UK
	BX-85C	Classical	NYMC	NIBSC, UK NIID, Japan NYMC, USA
B/Brisbane/35/2018	Wild type virus			NIBSC, UK
B/Victoria/705/2018	Wild type virus			NIBSC, UK NIID, Japan
	BVR-11	Classical	VIDRL	CCDC, China FCI, UK NIBSC, UK NIID, Japan VIDRL, Australia
B/Sichuan-Gaoxin/531/2018	Wild type virus			WHO CCs
	BX-83A	Classical	NYMC	CCDC, China NYMC, USA
	CNIC-1906	Classical	CCDC	CCDC, China FCI, UK NIBSC, UK VIDRL, Australia

Institutes contact details for candidate vaccine virus orders/information:

CCDC: whocc-china@cnic.org.cn
CDC: pdx1@cdc.gov (Subject: CVV request)
FCI: whocc@crick.ac.uk
NIBSC: standards@nibsc.org or enquiries@nibsc.org

¹ For cell-derived candidate vaccine viruses and reference reagents please see https://www.who.int/influenza/vaccines/virus/candidates_reagents/home/en/

² https://www.who.int/immunization_standards/national_regulatory_authorities%20/offices/

NIID: flu-vaccine@nih.go.jp
NYMC: doris_bucher@nymc.edu
VIDRL: whoflu@influenzacentre.org
WHO CCs: http://www.who.int/influenza/gisrs_laboratory/collaborating_centres/list/en/

Reference antigens (freeze-dried)

Parent virus	Starting materials		Ref Ag Lot number	Unitage (µg HA/ml)	Available from
	Candidate vaccine virus	Egg or cell			
B/Washington/02/2019	Wild type	Egg	B(v)-Ag-1912	77	CBER/FDA, USA
			19/238	76	NIBSC, UK
		Recombinant HA	B(v)-Ag-2004	52	CBER/FDA, USA
B/Victoria/705/2018	BVR-11	Egg	2020BVA	72	NIID, Japan
			2020BVB	39	NIID, Japan
			19/208	79	NIBSC, UK
			2019/130B	89	TGA, Australia
B/Darwin/7/2019	Wild type	Cell	B(v)-Ag-2002	41	CBER/FDA, USA
			19/210	44**	NIBSC, UK

** after reconstitution in 0.5 ml of water

Sheep antisera

Purified HA from		Order Lot number	Available from
Parent virus	Egg or Cell		
B/Washington/02/2019 – like	Egg	2020BV-1	NIID, Japan
		19/218	NIBSC, UK
		B(v)-Ab-2014	CBER/FDA, USA
		B(v)-Ab-1914[#]	CBER/FDA, USA
		AS436	TGA, Australia

New reagents shown in blue

[#] low volume

The above-listed potency testing reagents have been developed with support from manufacturers and calibrated by the WHO Essential Regulatory Laboratories (ERLs) of the Global Influenza Surveillance and Response System (GISRS).

ERLs contact details for reagents orders/information:

CBER/FDA: CBERShippingRequests@fda.hhs.gov
NIBSC: standards@nibsc.org or enquiries@nibsc.org
NIID: flu-vaccine@nih.go.jp
TGA: influenza.reagents@health.gov.au

The list of all WHO Collaborating Centres (CCs) and Essential Regulatory Laboratories (ERLs) for influenza can be found on the WHO web site at

http://www.who.int/influenza/gisrs_laboratory/collaborating_centres/

For other candidate vaccine viruses and potency testing reagents, please go to http://www.who.int/influenza/vaccines/virus/candidates_reagents/home/en/

For general enquiries, please contact gisrs-whohq@who.int